Article Details

Sumitomo Pharma Oncology Presents Preliminary Data from Phase 1/2 Clinical Study ...

Retrieved on: 2022-12-10 23:13:53

Tags for this article:

Click the tags to see associated articles and topics

Sumitomo Pharma Oncology Presents Preliminary Data from Phase 1/2 Clinical Study .... View article details on hiswai: https://www.prnewswire.com/news-releases/sumitomo-pharma-oncology-presents-preliminary-data-from-phase-12-clinical-study-evaluating-investigational-agent-tp-3654-in-patients-with-myelofibrosis-at-american-society-of-hematology-2022-annual-meeting--exposition-301699788.html

Excerpt

The dose escalation portion of the study has enrolled 9 patients at the time of the analysis. To date, five dose levels of TP-3654 were evaluated, ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up